Could a vaccine tame chronic hepatitis b?
NCT ID NCT05841095
First seen Jun 18, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This early-stage trial tests a therapeutic vaccine called ISA104 in 24 people with chronic hepatitis B who are already on antiviral drugs. The goal is to see if the vaccine is safe and can boost the immune system to better fight the virus. Participants will receive either ISA104 or a placebo, and researchers will monitor side effects and immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Erasmus MC
Rotterdam, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ISA104 (therapeutic hepatitis B virus synthetic long peptide vaccine)
What this could lead to
If successful, ISA104 could help control chronic hepatitis B by boosting the immune system, potentially reducing the need for lifelong antiviral medication.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply widely. The vaccine may not trigger a strong enough immune response or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.